Literature DB >> 20676053

The future of monoclonal antibody technology.

Alexander Zider1, Donald L Drakeman2.   

Abstract

With the rapid growth of monoclonal antibody-based products, new technologies have emerged for creating modified forms of antibodies, including fragments, conjugates and multi-specific antibodies. We created a database of 450 therapeutic antibodies in development to determine which technologies and indications will constitute the "next generation" of antibody products. We conclude that the antibodies of the future will closely resemble the antibodies that have already been approved for commercial sale.

Mesh:

Substances:

Year:  2010        PMID: 20676053      PMCID: PMC3180083          DOI: 10.4161/mabs.12461

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  5 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Monoclonal antibody successes in the clinic.

Authors:  Janice M Reichert; Clark J Rosensweig; Laura B Faden; Matthew C Dewitz
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

3.  Upping the ante on antibodies.

Authors:  Monya Baker
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 4.  Potent antibody therapeutics by design.

Authors:  Paul J Carter
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

5.  Development trends for therapeutic antibody fragments.

Authors:  Aaron L Nelson; Janice M Reichert
Journal:  Nat Biotechnol       Date:  2009-04       Impact factor: 54.908

  5 in total
  2 in total

Review 1.  Metrics for antibody therapeutics development.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 2.  Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers.

Authors:  Roghaye Arezumand; Abbas Alibakhshi; Javad Ranjbari; Ali Ramazani; Serge Muyldermans
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.